Illumina announces FDA-approved NGS cancer companion test kit


By LabOnline Staff
Friday, 07 July, 2017


Illumina has announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit.

This kit is intended to be used on the Illumina MiSeqDx System and enables laboratories to help clinicians identify which patients are eligible for treatment of metastatic colorectal cancer with Vectibix (panitumumab).

As the first monoclonal anti-epidermal growth factor receptor (EGFR) antibody approved by the FDA for use in combination with FOLFOX for first-line treatment for patients with wild-type RAS metastatic colorectal cancer (mCRC), Vectibix represents an innovative treatment option for these patients. The improvement of both overall survival and progression-free survival seen with Vectibix in combination with FOLFOX in patients with wild-type RAS mCRC highlights the importance of expanded biomarker screening to optimise cancer treatment planning.

“Together with Amgen, we’ve developed a companion diagnostic test kit that interrogates 56 variants across the KRAS and NRAS genes in order to establish mutant status in a single test. Through the Extended RAS Panel, clinicians will be able to identify patients with wild-type RAS genes who may benefit from treatment with Vectibix,” shared Garret Hampton, PhD, Executive Vice President, Clinical Genomics at Illumina.

“As we expand our understanding of the genomic drivers of cancer, next-generation sequencing has the potential to transform cancer therapeutics by informing development of targeted therapies and by delivering integrated testing platforms to identify the right therapy for the right patient,” said Francis deSouza, President and CEO of Illumina.

Related News

Calibration standard moves to final stage of revision

The International Organization for Standardization (ISO) is revising ISO/IEC 17025, General...

Quantum technology for imaging life at the nanoscale

Researchers have demonstrated a way to detect and image electronic spins non-invasively with...

A concord of chemistry and crystallography

Researchers have released a theoretical approach to explain inconsistencies between...


  • All content Copyright © 2017 Westwick-Farrow Pty Ltd